参考文献：

1.Han, B. et al. (2024) ‘Cancer incidence and mortality in China, 2022’, Journal of the National Cancer Center, 4(1), pp. 47–53. 

2.Chinese Association for Lung Cancer, Chinese Medical Association Oncology Branch Lung Cancer Group, and Chinese Thoracic Oncology Group (2021) ‘Guidelines for adjuvant therapy after complete resection of stage I–IIIB non-small cell lung cancer (2021 edition)’, National Medical Journal of China, 101(16), pp. 1132–1142. doi:10.3760/cma.j.cn112137-20210210-00406.

3.Sorscher, S. (2024) ‘Perioperative Nivolumab in Resectable Lung Cancer’, New England Journal of Medicine, 391(6), p. 573.

4.Wu, L. et al. (2024) ‘Perioperative nivolumab (NIVO) in patients (pts) with resectable stage II–IIIB NSCLC: CheckMate 77T Chinese population analysis’, ESMO Asia 2024, 594P.